U.S. Markets closed

Momenta Pharmaceuticals, Inc. (MNTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.50+0.20 (+1.23%)
At close: 4:00PM EDT

16.50 0.00 (0.00%)
After hours: 4:29PM EDT

People also watch
ALNYACORNBIXMDCOVNDA
Full screen
Previous Close16.30
Open16.30
Bid16.40 x 100
Ask16.55 x 100
Day's Range16.15 - 16.65
52 Week Range10.50 - 19.90
Volume280,386
Avg. Volume806,900
Market Cap1.22B
Beta2.04
PE Ratio (TTM)-39.57
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : July 28, 2017
    Capital Cube7 hours ago

    Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : July 28, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Momenta Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Reuters7 days ago

    U.S. jury sides with Amphastar over Momenta in drug patent trial

    A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.

  • American City Business Journals7 days ago

    ​Jury nixes Momenta patent case that sought $938M in damages

    A federal jury has rejected a $938 million lawsuit filed by Momenta Pharmaceuticals that accused a California drugmaker of infringing its patent covering a generic blood-thinner. According to court records, the jury ruled Friday that while Amphastar Pharmaceuticals (AMPH) infringed Momenta’s (MNTA) patent for testing the quality of batches of the drug, the patent was invalid. Momenta and its partner, Novartis unit Sandoz, had sought $938 million in damages in the trial, which began July 11.